Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Current Assets: 2009-2025

Historic Current Assets for Cytokinetics (CYTK) over the last 16 years, with Sep 2025 value amounting to $977.3 million.

  • Cytokinetics' Current Assets fell 4.05% to $977.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $977.3 million, marking a year-over-year decrease of 4.05%. This contributed to the annual value of $1.1 billion for FY2024, which is 76.41% up from last year.
  • Per Cytokinetics' latest filing, its Current Assets stood at $977.3 million for Q3 2025, which was up 10.24% from $886.5 million recorded in Q2 2025.
  • Cytokinetics' 5-year Current Assets high stood at $1.1 billion for Q4 2024, and its period low was $364.2 million during Q2 2021.
  • Its 3-year average for Current Assets is $828.2 million, with a median of $886.5 million in 2025.
  • As far as peak fluctuations go, Cytokinetics' Current Assets skyrocketed by 91.70% in 2021, and later tumbled by 36.51% in 2023.
  • Cytokinetics' Current Assets (Quarterly) stood at $535.7 million in 2021, then skyrocketed by 48.45% to $795.2 million in 2022, then fell by 21.02% to $628.1 million in 2023, then spiked by 76.41% to $1.1 billion in 2024, then decreased by 4.05% to $977.3 million in 2025.
  • Its Current Assets was $977.3 million in Q3 2025, compared to $886.5 million in Q2 2025 and $956.1 million in Q1 2025.